Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-κB activation and nuclear factor-κB-regulated gene transcription through inactivating inhibitory κB kinase β

Molecular Pharmacology

Volumn 73, Issue 4, 2008, Pages 1309-1318

  Byung, Hak Kim ^a   Roh, Eunmiri ^a   Hwa, Young Lee ^a   Lee, In Jeong ^a   Ahn, Byeongwoo ^a   Jung, Sang Hun ^b   Lee, Heesoon ^a   Han, Sang Bae ^a   Kim, Youngsoo ^a  

^a Chungbuk National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6,6 DIMETHYL 2 (PHENYLIMINO) 6,7 DIHYDRO 5H BENZ[1,3]OXATHIOL 4 ONE; BOT 64; CYCLOOXYGENASE 2; ENZYME INHIBITOR; GLUTAMIC ACID; I KAPPA B ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SERINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; DNA BINDING; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PURIFICATION; EXPRESSION VECTOR; GENE CONTROL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SURVIVAL; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; CATALYSIS; CELL LINE; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; TRANSCRIPTION, GENETIC;

EID: 41149138938     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041251     Document Type: Article

References (38)

1. Acton RD, Dahlberg PS, Uknis ME, Klaerner HG, Fink GS, Norman JG, and Dunn DL (1996) Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors. Arch Surg 131:1216-1221.
2. Altavilla D, Squadrito G, Minutoli L, Deodato B, Bova A, Sardella A, Seminara P, Passaniti M, Urna G, Venuti SF, et al. (2002) Inhibition of nuclear factor-κB activation by IRFI 042 protects against endotoxin-induced shock. Cardiovasc Res 54:684-693.
3. Archer S (1993) Measurement of nitric oxide in biological models. FASEB J 7:349-360.
4. Aupperle KR, Bennett BL, Boyle DL, Tak P-P, Manning AM, and Firestein GS (1999) NF-κB regulation by IκB kinase in primary fibroblast-like synoviocytes. J Immunol 163:427-433.
5. Baeuerle PA and Baltimore D (1988) IκB: a specific inhibitor of the NF-κB transcription factor. Science 242:540-546.
6. Bernier M, Kwon YK, Pandey SK, Zhu TN, Zhao RJ, Maciuk A, He HJ, Decabo R, and Kole S (2006) Binding of manumycin A inhibits IκB kinase β activity. J Biol Chem 281:2551-2561.
7. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, and Adams J (2003) Novel IKK inhibitors: β-carbolines. Bioorg Med Chem Lett 13:2419-2422.
8. Chauhan SD, Seggara G, Vo PA, MacAllister RJ, Hobbs AJ, and Ahluwalia A (2003) Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. FASEB J 17:773-775.
9. Delhase M, Hayakawa M, Chen Y, and Karin M (1999) Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284:309-313.
10. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, and Karin M (1996) Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16:1295-1304.
11. Goeth H and Wildfeuer A (1969) Antimicrobial and cytostatic properties of 6-hydroxy-1,3-benzoxathiol-2-one. Arzneimittelforschung 19:1298-1304.
12. Guha M and Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85-94.
13. Hehner SP, Hofmann TG, Droge W, and Schmitz ML (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J Immunol 163:5617-5623.
14. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, and Bensi G (1993) Characterization of a functional NF-κB site in the human interleukin-1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13:6231-6240.
15. Jeon KI, Byun MS, and Jue DM (2003) Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp Mol Med 35:61-66.
16. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663.
17. Kim BH, Lee JY, Seo JH, Lee HY, Ryu SY, Ahn BW, Lee CK, Hwang BY, Han SB, and Kim Y (2007) Artemisolide is a typical inhibitor of IκB kinase β targeting cysteine-179 residue and down-regulates NF-κB-dependent TNF-α expression in LPS-activated macrophages. Biochem Biophys Res Commun 361:593-598.
18. Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, and Verma IM (1999a) IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13:1322-1328.
19. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, and Karin M (1999b) The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 189:1839-1845.
20. Liang M-C, Bardhan S, Li C, Pace EA, Porco JA Jr, and Gilmore TD (2003) Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase. Mol Pharmacol 64:123-131.
21. Liu SF and Malik AB (2006) NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290:L622-L645.
22. Lius V and Sennerfeldt P (1979) Local treatment of acne with tioxolone. Lakartidningen 76:39-41.
23. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, and Murphy WJ (1993) Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon -γ and lipopolysaccharide. Proc Natl Acad Sci U S A 90:9730-9734.
24. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, and Dorken B (2003) Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 102:1028-1034.
25. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, Zhou XD, Qiu Y, Zusi FC, and Burke JR (2003) A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 48:2652-2659.
26. Moon KY, Hahn BS, Lee J, and Kim YS (2001) A cell-based assay system for monitoring NF-κB activity in human HaCat transfectant cells. Anal Biochem 292:17-21.
27. Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, Shintani T, Sato H, Koriyama Y, Fukushima K, Nunami N, et al. (2004) Synthesis and structureactivity relationships of novel IKK-β inhibitors: orally active anti-inflammatory agents. Bioorg Med Chem Lett 14:4019-4022.
28. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, and Miyake K (2002) Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672.
29. O'Sullivan B, Thompson A, and Thomas R (2007) NF-κB as a therapeutic target in autoimmune disease. Expert Opin Ther Targets 11:111-122.
30. Olivier S, Robe P, and Bours V (2006) Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72:1054-1068.
31. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, and Zingarelli B (2002) Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 61:953-963.
32. Tian B and Brasier AR (2003) Identification of a nuclear factor κB-dependent gene network. Recent Prog Horm Res 58:95-130.
33. Weber CK, Liptay S, Wirth T, Adler G, and Schmid RM (2000) Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 119:1209-1218.
34. Yamamoto Y, Yin MJ, Lin KM, and Gaynor RB (1999) Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 274:27307- 27314.
35. Yao J, Mackman N, Edgington TS, and Fan S-T (1997) Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells: regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 272:17795-17801.
36. Yin MJ, Yamamoto Y, and Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396:77-80.
37. Zandi E, Chen Y, and Karin M (1998) Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 281:1360-1363.
38. Zhang Y, Broser M, and Rom WN (1994) Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-κB. Proc Natl Acad Sci U S A 91:2225-2229.